Xavier Barril - Gain Therapeutics Chief Officer
| GANX Stock | USD 1.86 0.12 6.90% |
Insider
Xavier Barril is Chief Officer of Gain Therapeutics
| Address | 4800 Montgomery Lane, Bethesda, MD, United States, 20814 |
| Phone | 301 500 1556 |
| Web | https://www.gaintherapeutics.com |
Gain Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7296) % which means that it has lost $0.7296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8883) %, meaning that it created substantial loss on money invested by shareholders. Gain Therapeutics' management efficiency ratios could be used to measure how well Gain Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.27 in 2024. Return On Capital Employed is likely to rise to -1.55 in 2024. At this time, Gain Therapeutics' Other Current Assets are fairly stable compared to the past year. Total Assets is likely to rise to about 20.2 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 12.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Eliem Therapeutics | 63 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| BS CPA | Inhibrx | 42 | |
| Kishor Bhatia | Lantern Pharma | 69 | |
| William Ho | In8bio Inc | 45 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Dr III | Cue Biopharma | 48 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Paul Manley | Tff Pharmaceuticals | N/A | |
| Anthony Hickey | Tff Pharmaceuticals | N/A | |
| Kate Rochlin | In8bio Inc | 42 | |
| Kenneth LaMontagne | In8bio Inc | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Lawrence Lamb | In8bio Inc | 69 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| James JD | Eliem Therapeutics | 58 | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Harlan Weisman | Tff Pharmaceuticals | 72 | |
Management Performance
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.73 |
Gain Therapeutics Leadership Team
Elected by the shareholders, the Gain Therapeutics' board of directors comprises two types of representatives: Gain Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gain. The board's role is to monitor Gain Therapeutics' management team and ensure that shareholders' interests are well served. Gain Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gain Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gianluca Fuggetta, Principal Reporting | ||
| Xavier Barril, Chief Officer | ||
| LLM IUR, CEO President | ||
| Joanne Taylor, Senior Research | ||
| Terenzio PharmD, Senior Operations | ||
| Salvatore Calabrese, CFO Sec | ||
| Khalid Islam, Executive Chairman | ||
| Jonas MD, Chief Officer | ||
| Ana GarciaCollazo, Head Research | ||
| Natalia PerezCarmona, Head Biology | ||
| Manolo Bellotto, GM Officer | ||
| Evan Ballantyne, CFO Secretary | ||
| Gene MBA, Chief Officer |
Gain Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gain Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 34.87 M | ||||
| Shares Outstanding | 26.53 M | ||||
| Shares Owned By Insiders | 5.09 % | ||||
| Shares Owned By Institutions | 7.96 % | ||||
| Number Of Shares Shorted | 718.74 K | ||||
| Price To Book | 5.18 X | ||||
| Price To Sales | 925.92 X | ||||
| Revenue | 55.18 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.